Justin Saeks and Bruce Carlsoneditorial@labpulse.comInfectiousAntigen tests drive COVID-19 test market to $10.5BEven in the fall of 2020, there are capacity limitations, questions about testing accuracy, and challenges with sample collection. But creative solutions have been emerging at labs to help ease the load during a difficult time.November 9, 2020Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community